Richard Wood’s Post

Interesting article regarding the future of cell and gene therapies and the cold chain logistics they require. Our VP of Cell and Gene Therapies Emilio Frattaruolo, CPPL is always happy to discuss your specific requirements!

It was a pleasure to sit down with Fierce Biotech to share my thoughts on the state of the cell and gene industry and the pivotal role that the cold chain is playing in it's progression. Watch the video below: #cellandgene #SupplyChainSolutions #ColdChain #TemperatureControl #PharmaSupplyChain #Logistics #Sustainability #Cryo

The journey from scientific discovery to commercial success in cell and gene therapy is full of challenges. These challenges were the focus of a recent panel at the #PharmaLifeSciences2024: Advancements in Cell and Gene Therapy virtual summit, featuring Likarda CEO, Dr. Stella K. Vnook. Key topics included scaling production, patient engagement, and navigating regulatory hurdles—along with strategies to overcome them. Thank you to TechTarget for summarizing this insightful discussion, which you can read here: https://lnkd.in/gpreEJes #CellTherapy #GeneTherapy #HealthcareInnovation #Biotech

The advent of cell and gene therapies is a promising shift in the healthcare landscape, yet it isn't without its unique challenges. From intricate manufacturing phases to regulatory complexities, these obstacles must be navigated for its full potential to be realized. In a recent interview with Clinical Leader, Roger Palframan, Head of US Research UCB, explores these issues - offering insight into how we can overcome them. Read it now: https://lnkd.in/dVvGxRE7 #CellAndGeneTherapy #HealthcareInnovation

Don't forget to sign up for the Biophysical Summit hosted by Applied Photophysics and KBI Biopharma! 🏔 This summit will highlight some of the latest analytical techniques for developing and characterizing protein and gene therapies. Come with your questions and learn how companies tackle the characterization of novel modalities! Register here: https://bit.ly/3TxZawo #BiophysicalSummit #KBI #AppliedPhotophysics

Engaging discussion on the challenges, emerging trends, and key value drivers shaping the Cell & Gene Therapy (C&GT) space, as well as the potential growth opportunities in Europe at Advanced Therapies Europe 2024. At Invivo Partners, we’re confident that the C&GT field will continue to advance, with promising expansions into new indications, the exploration of novel cell types, and the development of cutting-edge technologies to tackle the challenges ahead. #ATE24

Discover how decentralized manufacturing is reshaping the landscape of cell and gene therapy development in this blog capturing insights from our Bridging the Gap webinar series. Gain valuable insights from experts like Dorothea Ledergerber, PhD, Chief Technical Officer at Tigen Pharma, and Patrick Hanley, PhD, Director of the Cellular Therapy Program at Children’s National Hospital. Read the full blog and register for future webinars here: https://hubs.ly/Q02xHWy70 #CellTherapy #GeneTherapy #Innovation #WebinarSeries

Modular facilities, driven by the rise of cell and gene therapies, continuous manufacturing, and single-use technologies, help biomanufacturers meet clinical demands. Learn how we partnered with Siemens to create automation and digitization solutions for streamlined modular processing. Watch the video below and learn more in our white paper: https://sar.to/1xs07 #SimplifyingProgress #InThisTogether #Bioprocessing

Join Goodwin's Michael Shuster, Joshua Weinger, PhD, and Sarah Stoiber for the Cell + Gene Therapies Webinar: IP Due Diligence, to explore the unique IP issues faced by cell and gene therapies companies. This webinar will discuss: 🔹 Navigating patentability, freedom-to-operate, and managing third-party risks 🔹 Best practices in conducting thorough and strategic IP reviews at important inflection points of a company's growth stages 🔹 Practical examples and lessons learned from working with leading companies in the life sciences sector Register here: https://bit.ly/3TpAl5f #IntellectualProperty #LifeSciences

📣Extra! Extra! Don't just read all about it. Do something about it! Artemetrx GeneCQ is a groundbreaking tool that empowers healthcare payers to accurately predict financial exposure to high-cost gene therapies. Schedule a demo to see it for yourself!